 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

After meeting with the FDA, Company to submit a supplemental New Drug Application (sNDA) to FDA in Q1 2024 for conversion of the existing U.S. accelerated approval of FILSPARI (sparsentan) in IgAN...

Travere Completes Successful pre-NDA Meeting for FILSPARI in IgAN; Provides Regulatory Updates for both IgAN and FSGS

Travere Therapeutics, Inc. (NASDAQ:TVTX  Get Free Report) was the target of a significant growth in short interest during the month of November. As of November 15th, there was short interest...

Travere Therapeutics, Inc. (NASDAQ:TVTX) Short Interest Update

SAN DIEGO, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will present at the 6th Annual Evercore ISI HealthCONx Conference on...

Travere Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference

In a report released today, Allison Bratzel from Piper Sandler maintained a Hold rating on Travere Therapeutics (TVTX Research Report), with a pr...

Piper Sandler Sticks to Their Hold Rating for Travere Therapeutics (TVTX)

This is a signal that TVTX's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options...

Travere Therapeutics (TVTX, $5.58) RSI Indicator left the oversold zone on November 10, 2023

Travere Therapeutics (TVTX, $5.44) RSI Indicator left the oversold zone on November 09, 2023

This price move could be a signal that TVTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options...

Travere Therapeutics (TVTX, $5.44) price may climb as it broke lower Bollinger Band on Nov 09, 2023

Travere Therapeutics, Inc. (NASDAQ:TVTX) Q3 2023 Earnings Call Transcript November 7, 2023 Travere Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-1.17 EPS, expectations were...

Travere Therapeutics, Inc. (NASDAQ:TVTX) Q3 2023 Earnings Call Transcript

Received 430 new patient start forms for FILSPARI (sparsentan) in the third quarter of 2023; demand and payer coverage continued to grow Net product sales of FILSPARI totaled $8 million for the...

Travere Therapeutics Reports Third Quarter 2023 Financial Results

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Travere Therapeutics to present data from clinical studies of sparsentan

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

Watchers	658
52-Wk Low	$5.25
52-Wk High	$23.18

Market Cap	$482.44M
Volume (M)	1.03M
52-Wk High	$23.18
52-Wk Low	$5.25

TVTX Travere Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals